3 › 3.3 › 3.3.1
3.3.1 Classification based on LVEF
Pages 16–17 · open in PDF
Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.
Page 16 · PDF
3.2.1. Epidemiology of heart failure phenotypes In population-based samples, nearly half of all HF cases have HF with preserved ejection fraction (HFpEF), and this proportion may be increasing due to better treatment of coronary artery disease (CAD) and the rising burden of hypertension, obesity, and other HFpEF risk factors.21 Patients with HFpEF are older and are more often female. The Swedish HF registry reported an average age at HFpEF onset of 77 years with 55% female.22 In patients with heart failure with reduced ejection fraction (HFrEF), 71% were male and the mean age at onset was 72 years.22 Several subtypes of HFpEF have been suggested, with up to 50% of patients having a predominantly metabolic/obesity subtype [younger, higher body mass index (BMI)] in some regions, and up to 50% with a predominantly ageing, vascular subtype [older, stiff arteries, high prevalence of chronic kidney disease (CKD)] in other regions.23,24 Heart failure with reduced ejection fraction is often subdivided into ischaemic vs non-ischaemic aetiologies, with approximately half of all cases being considered ischaemic.
3.2.2. Natural history and prognosis Although the mortality rates after HF onset have improved considerably over the past three decades, the 5-year overall survival rates are still <60%.25,26 For younger patients, data from Denmark suggest survival has improved with contemporary management, with a current 5-year mortality rate of 15% for patients <65 years and 39% for patients aged 65–79 years.25 In patients ≥80 years, improvements in mortality have also been observed, although these improvements are not as pronounced as those observed in younger patients, partly due to a greater burden of comorbidity and a greater proportion of non-CV mortality in the elderly.17,25,27 Mortality may be lower in HFpEF than HFrEF, but overall differences are small as patients with HFpEF are considerably older, and the risk of hospitalization is similar.28,29 Patients diagnosed with HF in an outpatient setting have better
prognosis than patients diagnosed during a HFH, and patients with repeated HFH have a particularly high risk of mortality.30,31 The overall burden of HF as well as HFH can be expected to rise over the next few decades due to greater survival, an ageing population, and greater prevalence of risk factors and obesity in the younger population.
3.3. Classifications 3.3.1. Classification based on left ventricular ejection fraction Traditionally, HF has been divided into distinct phenotypes based on the measurement of LVEF. In the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, three different HF phenotypes were identified: HFrEF (LVEF ≤40%); HF with mildly reduced ejection fraction (HFmrEF, LVEF 41%–49%); and HFpEF (LVEF ≥50%).3 The rationale behind this classification relates to the inclusion criteria of the trials of therapies that improved outcomes in patients with HF and LVEF ≤40%. The HFmrEF phenotype was introduced to focus on patients usually not included in HFrEF trials. The nomenclature was changed from ‘mid-range’ to ‘mildly reduced’ to highlight that patients with HFmrEF are similar to patients with HFrEF in terms of both clinical characteristics, outcomes, and response to treatments.32,33 Patients with HFmrEF have similar underlying aetiology of HF to patients with HFrEF, and the pathophysiology of HFmrEF is more similar to HFrEF (reduced contractility and systolic dysfunction) than HFpEF (increased stiffness and diastolic dysfunction).34 In addition, the efficacy of medical treatment of HFmrEF is more similar to HFrEF than HFpEF.35–45 Finally, it is important to consider LVEF trajectories, as many patients with LVEF 41%–49% may experience a deterioration in LVEF.46 The Task Force for the 2026 ESC Guidelines for the management of heart failure has eliminated the phenotype of HFmrEF and reclassified HF based on a pathophysiological classification of HF, including two distinct phenotypes: (i) HFrEF: characterized by LVEF <50% and symptoms and/or signs of HF. (ii) HFpEF: characterized by LVEF ≥50% and symptoms and/or signs of HF and objective evidence of cardiac structural and/ or functional abnormalities consistent with the presence of left ventricular (LV) diastolic dysfunction/raised LV filling pressures, supported by raised natriuretic peptides. Using a single LVEF value as cut-point for distinguishing HFpEF and HFrEF is somewhat arbitrary and has to be evaluated in the clinical situation, as there is variability in measurement depending both on the modality and the interpreter. Furthermore, LVEF may be falsely high in certain situations, e.g. mitral regurgitation (MR). Natriuretic peptides may be used as supportive evidence for the diagnosis of HF. Importantly, drug and device therapies can lead to positive LV reverse remodelling in patients with HFrEF and, thus, improvement of LVEF. Patients with HFrEF and improved LVEF have a more favourable prognosis. However, it is important to ensure that these patients are still managed with optimal medical therapy except for selected patients. The current definition of improved LVEF requires an increase of at least 10% in LVEF (absolute) and must be at least above 40% (often normal).47
variations.12,13 Both the incidence and prevalence of HF are increasing with age and risk-factor burden, with wide variation depending on the population and setting studied and the diagnostic criteria used.14 In addition, several factors, such as level of education, income, neighbourhood deprivation, climate, and air pollution, influence the risk of HF, contributing to varying epidemiology worldwide.13 In European countries, current prevalance-estimates range from 12–58 cases per 1000 people.15 As a result of the growing cohort of older people in Western populations, the crude incidence of HF has been increasing and is currently 2–13 per 1000 person-years in Europe (ranging from <1 per 1000 person-years for people aged 45–54 years to >12 per 1000 person-years for people aged >74 years).16,17 However, age-adjusted HF incidence rates have been declining over the past three decades, probably because of better risk-factor control and treatment of CV conditions.15,17,18 Among younger adults, incidence rates of HF appear to be either increasing or stagnating. There are several possible explanations for this, including (i) a greater burden of CV risk factors, (ii) increasing numbers of patients with congenital heart disease reaching adulthood, and (iii) a change in surveillance patterns.16,19,20 Furthermore, the mortality of HF has improved, which has led to a higher prevalence of HF.13
Page 17 · PDF
3.3.2. Classification based on heart failure stages An additional classification based on HF stages has been proposed previously.4 The Task Force has included this classification as we focus more on prevention of HF and early diagnosis (Figure 2).
3.3.3. Other classifications of heart failure
3.3.4. Classifications of treatments in heart failure The term guideline-directed medical therapy (GDMT) was introduced in the 2013 ACCF/AHA Guideline for the management of heart failure and is the cornerstone of pharmacological treatment for patients with HF.49 The term was meant to represent optimal medical therapy primarily with a Class I recommendation, which at that time included treatment with angiotensin-
Figure 2 Heart failure stages and classifications. AMT, additional medical therapy; FMT, foundational medical therapy; GDIT, guidelinedirected interventional therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction. aSee section 4.1. Not all will develop HF, but risk factor intervention may be warranted. bFor example, left ventricular hypertrophy, cardiac chamber enlargement, ventricular wall motion abnormality, myocardial tissue abnormality (e.g. evidence of myocardial oedema, scar/fibrosis abnormality by T2-weighted cardiac magnetic resonance imaging or late gadolinium enhancement imaging), valvular heart disease. cFor example, reduced left or right ventricular systolic function, evidence of increased filling pressures (by invasive or non-invasive measures), abnormal diastolic function. dEspecially in the setting of exposure to cardiotoxins. eFor details see Table 14.
Heart failure can also be classified according to clinical presentation: de novo (patients without a previous diagnosis of HF) vs pre-existing (patients with a diagnosis of HF), and chronic HF vs decompensated HF (DHF). Chronic HF may deteriorate to DHF. Details on the definitions and subtypes of DHF are provided in Section 7. Finally, an additional classification in isolated left-sided HF vs isolated right-sided HF vs combined left- and right-sided HF can be used. The main aetiology of chronic right-sided HF is LV dysfunction-induced pulmonary hypertension [World Health
Organization (WHO) group 2] leading to combined left- and right-sided HF. However, there are a number of causes of isolated right-sided HF, e.g. right ventricular (RV) myocardial infarction (MI); arrhythmogenic RV cardiomyopathy (ARVC); pulmonary hypertension WHO groups 1, 3, 4, and 5; and tricuspid or pulmonary valve regurgitation. Diagnosis and management of chronic right-sided HF is covered comprehensively in a recent Heart Failure Association (HFA) position paper.48